CMPX
Compass Therapeutics Inc
NASDAQ · Biotechnology
$6.52
+0.30 (+4.82%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.10M | 182.11M | 191.80M | 150.00M |
| Net Income | -63,923,639 | -42,646,254 | -48,286,720 | -30,029,624 |
| EPS | — | — | — | — |
| Profit Margin | -5,808.8% | -23.4% | -25.2% | -20.0% |
| Rev Growth | — | -8.0% | +10.9% | +1.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 190.71M | 178.18M | 172.82M |
| Total Equity | — | 650.14M | 615.47M | 679.35M |
| D/E Ratio | — | 0.29 | 0.29 | 0.25 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -72,603,309 | -49,107,977 | -55,425,546 | -48,007,831 |
| Free Cash Flow | — | -37,978,554 | -43,960,363 | -47,756,173 |